Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View
by Zacks Equity Research
Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.
CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate
by Zacks Equity Research
Within CVS Health's (CVS) Retail/LTC, the coronavirus pandemic results in greater use of 90-day prescriptions and early refills of maintenance medications in the quarter.
Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.
Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen (INGN) reported growth in business-to-business international and domestic revenues in Q1.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States showcased solid results in Q1.
Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from growth in Discover & Analytics Solutions segment. However, forex remains a woe.
Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) sees dismal performance by Dental arm in Q1 due to disruptions resulting from the coronavirus pandemic.
Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2020 results reflect sales growth across few major segments despite the coronavirus pandemic.
Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) benefits from increased product demand due to the coronavirus outbreak.
Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down
by Zacks Equity Research
The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.
Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.
Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View
by Zacks Equity Research
Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.
Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on the experimental coronavirus treatment when Gilead (GILD) reports first-quarter 2020 results.
The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen
Focus on Coronavirus Treatments to Boost Biotech Stocks
by Zacks Equity Research
With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.
Top Research Reports for Intel, Novartis & Toyota
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Novartis (NVS) and Toyota Motor (TM).
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter. Stock declines.
AbbVie Gets FDA Nod for Imbruvica+Rituxan in First-Line CLL
by Zacks Equity Research
AbbVie's (ABBV) regulatory application seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan gets approval from the FDA.
Roche's Ocrevus Line Extension Application Moves Forward
by Zacks Equity Research
Roche's (RHHBY) regulatory applications seeking approval for shorter infusion time for administration of multiple sclerosis drug, Ocrevus, move forward in the United States and Europe.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Biogen's (BIIB) performance when it reports first-quarter results.
Growth in New Drugs to Give a Boost to Roche (RHHBY) Q1 Sales
by Zacks Equity Research
Roche's (RHHBY) newer drugs are likely to have combated the biosimilar competition for legacy drugs in the first quarter.